Canadian Appro For Inex' Onco TCS Trial

12 May 1996

Inex has received approval from the Canadian Health Protection Branch for a Phase II trial of its anticancer drug Onco TCS (vincristine) in patients with pancreatic and metastatic colorectal cancer. A Phase I trial showed the product's potential in currently-untreatable pancreatic cancer. Statistics from the American Cancer Society, StatsCan and Health and Welfare Canada indicate that an estimated 27,000 North Americans are diagnosed each year with pancreatic cancer, and about 154,000 are diagnosed with colorectal cancer.

Onco TCS and the company's other drugs are based on Inex' proprietary technology called transmembrane carrier systems. The therapeutic agent combined with a TCS formulation is carried to disease sites and into diseased cells in higher concentration and for a longer duration than when given without TCS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight